Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727

Nature

Volumn 553, Issue 7686, 2018, Pages 111-114

  Robertson, Nathan ^a   Rappas, Mathieu ^a   Doré, Andrew S ^a   Brown, Jason ^a   Bottegoni, Giovanni ^a   Koglin, Markus ^a   Cansfield, Julie ^a   Jazayeri, Ali ^a   Cooke, Robert M ^a   Marshall, Fiona H ^a  

^a Heptares Therapeutics Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5A RECEPTOR; N,N BIS(1,3 BENZODIOXOL 5 YLMETHYL) 1 BUTYL 2,4 DIPHENYL 1H IMIDAZOLE 5 METHANAMINE; 1,3 BENZODIOXOLE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR; C5AR1 PROTEIN, HUMAN; FFAR1 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; IMIDAZOLE DERIVATIVE; N,N-BIS(1,3-BENZODIOXOL-5-YLMETHYL)-1-BUTYL-2,4-DIPHENYL-1H-IMIDAZOLE-5-METHANAMINE;

BIOAVAILABILITY; BONE; CELLS AND CELL COMPONENTS; DISEASE INCIDENCE; DISEASE TREATMENT; DRUG; INFECTIOUS DISEASE; NERVOUS SYSTEM DISORDER; PRIMATE; PROTEIN;

ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; HEK293 CELL LINE; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; GENETICS; INVERSE AGONISM; METABOLISM; MOLECULAR MODEL; MUTATION; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; X RAY CRYSTALLOGRAPHY;

GERBILLINAE; PRIMATES;

ANIMALS; BENZODIOXOLES; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DRUG INVERSE AGONISM; HEK293 CELLS; HUMANS; IMIDAZOLES; MODELS, MOLECULAR; MUTATION; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85040188959     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature25025     Document Type: Article

References (44)

1. Woodruff, T. M., Nandakumar, K. S. & Tedesco, F. Inhibiting the C5-C5a receptor axis. Mol. Immunol. 48, 1631-1642 (2011).
2. Klos, A., Wende, E., Wareham, K. J. & Monk, P. N. International Union of Basic and Clinical Pharmacology. Complement peptide C5a, C4a, and C3a receptors. Pharmacol. Rev. 65, 500-543 (2013).
3. Landlinger, C. et al. Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer's disease. J. Neuroinflammation 12, 150 (2015).
4. Hutchison, A. J. & Krause, J. E. The discovery of small molecule C5a antagonists. Annu. Rep. Med. Chem. 39, 139-147 (2004).
5. Sumichika, H. et al. Identification of a potent and orally active non-peptide C5a receptor antagonist. J. Biol. Chem. 277, 49403-49407 (2002).
6. Brodbeck, R. M. et al. Identification and characterization of NDT 9513727 [N, N-bis(1, 3-benzodioxol-5-ylmethyl)-1-butyl-2, 4-diphenyl-1H-imidazole-5-methanamine], a novel, orally bioavailable C5a receptor inverse agonist. J. Pharmacol. Exp. Ther. 327, 898-909 (2008).
7. Serrano-Vega, M. J., Magnani, F., Shibata, Y. & Tate, C. G. Conformational thermostabilization of the1-adrenergic receptor in a detergent-resistant form. Proc. Natl Acad. Sci. USA 105, 877-882 (2008).
8. Robertson, N. et al. The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery. Neuropharmacology 60, 36-44 (2011).
9. Oswald, C. et al. Intracellular allosteric antagonism of the CCR9 receptor. Nature 540, 462-465 (2016).
10. White, J. F. et al. Structure of the agonist-bound neurotensin receptor. Nature 490, 508-513 (2012).
11. Zhang, D. et al. Two disparate ligand-binding sites in the human P2Y1 receptor. Nature 520, 317-321 (2015).
12. Cheng, R. K. Y. et al. Structural insight into allosteric modulation of proteaseactivated receptor 2. Nature 545, 112-115 (2017).
13. Jazayeri, A. et al. Extra-helical binding site of a glucagon receptor antagonist. Nature 533, 274-277 (2016).
14. Lu, J. et al. Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40. Nat. Struct. Mol. Biol. 24, 570-577 (2017).
15. Waters, S. M. et al. Molecular characterization of the gerbil C5a receptor and identification of a transmembrane domain V amino acid that is crucial for small molecule antagonist interaction. J. Biol. Chem. 280, 40617-40623 (2005).
16. Rasmussen, S. G. et al. Crystal structure of the2 adrenergic receptor-Gs protein complex. Nature 477, 549-555 (2011).
17. Rasmussen, S. G. et al. Structure of a nanobody-stabilized active state of the2 adrenoceptor. Nature 469, 175-180 (2011).
18. Tehan, B. G., Bortolato, A., Blaney, F. E., Weir, M. P. & Mason, J. S. Unifying family A GPCR theories of activation. Pharmacol. Ther. 143, 51-60 (2014).
19. Floyd, D. H. et al. C5a receptor oligomerization. II. Fluorescence resonance energy transfer studies of a human G protein-coupled receptor expressed in yeast. J. Biol. Chem. 278, 35354-35361 (2003).
20. Klco, J. M., Lassere, T. B. & Baranski, T. J. C5a receptor oligomerization. I. Disulfide trapping reveals oligomers and potential contact surfaces in a G protein-coupled receptor. J. Biol. Chem. 278, 35345-35353 (2003).
21. Rabiet, M. J., Huet, E. & Boulay, F. Complement component 5a receptor oligomerization and homologous receptor down-regulation. J. Biol. Chem. 283, 31038-31046 (2008).
22. Cherezov, V. et al. High-resolution crystal structure of an engineered human2-adrenergic G protein-coupled receptor. Science 318, 1258-1265 (2007).
23. Hebert, T. E. et al. A peptide derived from a2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J. Biol. Chem. 271, 16384-16392 (1996).
24. Wu, B. et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066-1071 (2010).
25. Manglik, A. et al. Crystal structure of the ?-opioid receptor bound to a morphinan antagonist. Nature 485, 321-326 (2012).
26. Wu, H. et al. Structure of the human ?-opioid receptor in complex with JDTic. Nature 485, 327-332 (2012).
27. Wang, C. et al. Structure of the human smoothened receptor bound to an antitumour agent. Nature 497, 338-343 (2013).
28. Higginbottom, A. et al. Comparative agonist/antagonist responses in mutant human C5a receptors define the ligand binding site. J. Biol. Chem. 280, 17831-17840 (2005).
29. Caffrey, M. & Cherezov, V. Crystallizing membrane proteins using lipidic mesophases. Nat. Protocols 4, 706-731 (2009).
30. Kabsch, W. XDS. Acta Crystallogr. D 66, 125-132 (2010).
31. Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr. D 69, 1204-1214 (2013).
32. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50, 760-763 (1994).
33. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D 67, 235-242 (2011).
34. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
35. Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D 67, 355-367 (2011).
36. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486-501 (2010).
37. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213-221 (2010).
38. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12-21 (2010).
39. Harder, E. et al. OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. J. Chem. Theory Comput. 12, 281-296 (2016).
40. Martyna, G. J., Klein, M. L. & Tuckerman, M. Nosé-Hoover chains: the canonical emsemble via continuous dynamics. J. Chem. Phys. 97, 2635-2643 (1992).
41. Martyna, G. J., Tobias, D. J. & Klein, M. L. Constant pressure molecular dynamics algorithms. J. Chem. Phys. 101, 4177-4189 (1994).
42. Kräutler, V., van Gunsteren, W. F. & Hunenberger, P. H. A fast SHAKE algorithm to solve distance constraint equations for small molecules in molecular dynamics simulations. J. Comput. Chem. 22, 501-508 (2001).
43. Tuckerman, M., Berne, B. J. & Martyna, G. J. Reversible multiple time scale molecular dynamics. J. Chem. Phys. 97, 1990-2001 (1992).
44. Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. J. Mol. Graph. 14, 33-38, 27-28 (1996).